The BIT drug trial mentions no effect on CD4+ T cells which are the main barrier to a cure.
https://www.genengnews.com/topics/g...tent-hiv-1-offering-hope-of-functional-cures/
CD4+ T cells have been the most studied of the cellular reservoirs in which HIV-1 can persist. A small fraction of resting CD4+ T cells will harbor HIV-1, even during ART, and are considered to be “the major obstacle to HIV-1 eradication,” the authors point out. “Latent HIV-1 infection in resting CD4+ T cells is the primary cause of the barrier to a functional cure.”
- Forums
- ASX - By Stock
- BIT
- $10 Billion Deal
$10 Billion Deal, page-130
-
- There are more pages in this discussion • 13,138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $41.50M |
Open | High | Low | Value | Volume |
4.4¢ | 4.7¢ | 4.4¢ | $31.64K | 708.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 259000 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.6¢ | 17361 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 259000 | 0.045 |
1 | 200000 | 0.044 |
3 | 415000 | 0.043 |
3 | 322000 | 0.042 |
4 | 287000 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.047 | 200000 | 1 |
0.048 | 308915 | 1 |
0.050 | 21000 | 1 |
0.051 | 96225 | 3 |
0.052 | 1527335 | 2 |
Last trade - 14.10pm 21/06/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online